Positron emission tomography imaging approaches for external beam radiation therapies: Current status and future developments

British Journal of Radiology

Volumn 84, Issue SPEC. ISSUE 1, 2011, Pages

  Price, Pat M ^a   Green, M M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 60; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLTYROSINE F 18; METHIONINE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ACCURACY; BRAIN TUMOR; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSIMETRY; ESOPHAGUS CANCER; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK TUMOR; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPHOMA; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; THERAPY EFFECT; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; TUMOR VOLUME;

FLUORODEOXYGLUCOSE F18; FORECASTING; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TUMOR BURDEN;

EID: 82155182150     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/21263014     Document Type: Review

References (83)

1. Jones T. The role of positron emission tomography within the spectrum of medical imaging. Eur J Nucl Med 1996;23:207-11. (Pubitemid 26057001)
2. Jones T. The imaging science of positron emission tomography. Eur J Nucl Med 1996;23:807-13. (Pubitemid 26237876)
3. Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 2000;27:647-55.
4. Smith TA. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun 1998;19:97-105. (Pubitemid 28189177)
5. Lonsdale MN, Beyer T. Dual-modality PET/CT instrumentation - today and tomorrow. Eur J Radiol 2010;73:452-60.
6. 18F-FDG PET/CT examinations. J Nucl Med 2005;46:608-13.
7. Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 2009;251:166-74.
8. 18F-FDG. Radiat Prot Dosimetry 2010;139:208-13.
9. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S. (Pubitemid 32423895)
10. Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003;229:526-33. (Pubitemid 37310842)
11. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004;78:1017-23. (Pubitemid 39164825)
12. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7. (Pubitemid 36706537)
13. Fischer BM, Mortensen J. The future in diagnosis and staging of lung cancer: positron emission tomography. Respiration 2006;73:267-76. (Pubitemid 43725781)
14. NICE. The diagnosis and treatment of lung cancer. National Institute for Clinical Excellence, 2005. Available from: http://guidance.nice.org.uk.
15. Caldwell CB, Mah K, Skinner M, Danjoux CE. Can PET provide the 3D extent of tumor motion for individualized internal target volumes? A phantom study of the limitations of CT and the promise of PET. Int J Radiat Oncol Biol Phys 2003;55:1381-93. (Pubitemid 36338307)
16. Grosu A-L, Piert M, Molls M. Experience of PET for target localisation in radiation oncology. Br J Radiol 2005;28: 18-32. (Pubitemid 43154233)
17. Jarritt PH, Carson KJ, Hounsell AR, Visvikis D. The role of PET/CT scanning in radiotherapy planning. Br J Radiol 2006;79:S27-S35. (Pubitemid 44614401)
18. van Baardwijk A, Baumert BG, Bosmans G, van Kroonenburgh M, Stroobants S, Gregoire V, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 2006;32: 245-60. (Pubitemid 44502002)
19. MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009;91:85-94.
20. Rembielak A, Price P. The role of PET in target localization for radiotherapy treatment planning. Onkologie 2008;31:57-62. (Pubitemid 351252943)
21. Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol 2005;181:483-99. (Pubitemid 41059518)
22. Nestle U, Weber W, Hentschel M, Grosu AL. Biological imaging in radiation therapy: role of positron emission tomography. Phys Med Biol 2009;54:R1-25.
23. Carson KJ, Young VA, Cosgrove VP, Jarritt PH, Hounsell AR. Personnel radiation dose considerations in the use of an integrated PET-CT scanner for radiotherapy treatment planning. Br J Radiol 2009;82:946-9.
24. Vriens D, Visser EP, de Geus-Oei LF, Oyen WJ. Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging 2010;37:1408-25.
25. Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000;41:1491-4.
26. Bradley JD, Perez CA, Dehdashti F, Siegel BA. Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer. J Nucl Med 2004;45:96S-101S.
27. Schinagl DA, Vogel WV, Hoffmann AL, van Dalen JA, Oyen WJ, Kaanders JH. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography- based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:1282-9. (Pubitemid 47625859)
28. Nehmeh SA, Erdi YE. Respiratory motion in positron emission tomography/computed tomography: a review. Semin Nucl Med 2008;38:167-76. (Pubitemid 351466915)
29. Nehmeh SA, Erdi YE, Pan T, Pevsner A, Rosenzweig KE, Yorke E, et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 2004;31:3179-86. (Pubitemid 40064969)
30. Ford EC, Herman J, Yorke E, Wahl RL. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med 2009;50:1655-65.
31. Nestle U, Walter K, Schmidt S, Licht N, Nieder C, Motaref B, et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999;44:593-7. (Pubitemid 29258434)
32. Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 1999;175:356-73. (Pubitemid 29393147)
33. Troost EG, Schinagl DA, Bussink J, Boerman OC, van der Kogel AJ, Oyen WJ, et al. Innovations in radiotherapy planning of head and neck cancers: role of PET. J Nucl Med 2010;51:66-76.
34. Riegel AC, Berson AM, Destian S, Ng T, Tena LB, Mitnick RJ, et al. Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET/CT fusion. Int J Radiat Oncol Biol Phys 2006;65:726-32. (Pubitemid 43795841)
35. Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004;233:93-100. (Pubitemid 39280962)
36. Schwartz DL, Ford E, Rajendran J, Yueh B, Coltrera MD, Virgin J, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;61:129-36. (Pubitemid 40039114)
37. Scarfone C, Lavely WC, Cmelak AJ, Delbeke D, Martin WH, Billheimer D, et al. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med 2004;45:543-52. (Pubitemid 47618583)
38. Schinagl DA, Hoffmann AL, Vogel WV, van Dalen JA, Verstappen SM, Oyen WJ, et al. Can FDG-PET assist in radiotherapy target volume definition of metastatic lymph nodes in head-and-neck cancer? Radiother Oncol 2009;91:95-100.
39. Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N, et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 2004;73:269-75. (Pubitemid 39601073)
40. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603-9. (Pubitemid 28135606)
41. Lee YK, Cook G, Flower MA, Rowbottom C, Shahidi M, Sharma B, et al. Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiother Oncol 2004;73:277-83. (Pubitemid 39601074)
42. van Westreenen HL, Westerterp M, Sloof GW, Groen H, Bossuyt PM, Jager PL, et al. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg 2007;94:1515-20. (Pubitemid 350275631)
43. Westerterp M, Van Westreenen HL, Sloof GW, Plukker JT, Van Lanschot JJ. Role of positron emission tomography in the (re-)staging of oesophageal cancer. Scand J Gastroenterol Suppl 2006;116-22. (Pubitemid 43941074)
44. Plukker JT, van Westreenen HL. Staging in oesophageal cancer. Best Pract Res Clin Gastroenterol 2006;20:877-91. (Pubitemid 44391344)
45. Kneist W, Schreckenberger M, Bartenstein P, Grunwald F, Oberholzer K, Junginger T. Positron emission tomography for preoperative lymph node diagnosis in esophageal carcinoma. Chirurg 2003;74:922-30.
46. Zhong X, Yu J, Zhang B, Mu D, Zhang W, Li D, et al. Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2009;73:136-41.
47. Bouchelouche K, Choyke PL, Capala J. Prostate specific membrane antigen - a target for imaging and therapy with radionuclides. Discov Med 2010;9:55-61.
48. Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002;62:51-60. (Pubitemid 34121949)
49. Feng M, Kong FM, Gross M, Fernando S, Hayman JA, Ten Haken RK. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys 2009;73:1228-34.
50. Muijs CT, Schreurs LM, Busz DM, Beukema JC, van der Borden AJ, Pruim J, et al. Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Radiother Oncol 2009;93:447-53.
51. Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:64-74. (Pubitemid 41583543)
52. Feng R, Li MH, Kong L, Shi F, Yang GR, Yu JM. Correlation between PET-CT 18FDG uptake in primary lesions and clinicopathological parameters in esophageal carcinoma patients. Zhonghua Zhong Liu Za Zhi 2009;31:452-4.
53. Sovik A, Malinen E, Olsen DR. Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys 2009;73:650-8.
54. Guha C, Alfieri A, Blaufox MD, Kalnicki S. Tumor biology-guided radiotherapy treatment planning: gross tumor volume versus functional tumor volume. Semin Nucl Med 2008;38:105-13. (Pubitemid 351163200)
55. Schwartz DL, Ford EC, Rajendran J, Yueh B, Coltrera MD, Virgin J, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck 2005;27:478-87. (Pubitemid 40770816)
56. Seppala J, Seppanen M, Arponen E, Lindholm P, Minn H. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol 2009;93:234-40.
57. Brahme A. Recent advances in light ion radiation therapy. Int J Radiat Oncol Biol Phys 2004;58:603-16. (Pubitemid 38145595)
58. Dale RG, Jones B, Carabe-Fernandez A. Why more needs to be known about RBE effects in modern radiotherapy. Appl Radiat Isot 2009;67:387-92.
59. Fokas E, Kraft G, An H, Engenhart-Cabillic R. Ion beam radiobiology and cancer: time to update ourselves. Biochim Biophys Acta 2009;1796:216-29.
60. Flynn RT, Barbee DL, Mackie TR, Jeraj R. Comparison of intensity modulated X-ray therapy and intensity modulated proton therapy for selective subvolume boosting: a phantom study. Phys Med Biol 2007;52:6073-91. (Pubitemid 350093182)
61. Christian N, Lee JA, Bol A, De Bast M, Jordan B, Gregoire V. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol 2009;91:101-6.
62. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235-42. (Pubitemid 350251048)
63. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008;26:4449-57.
64. Kotz B, West C, Saleem A, Jones T, Price P. Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue. Mol Cancer Ther 2009;8:303-9.
65. Lehtio K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmaki L, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59:971-82. (Pubitemid 38834289)
66. Hicks RJ, MacManus MP, Matthews JP, Hogg A, Binns D, Rischin D, et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004;60:412-18. (Pubitemid 39233459)
67. van Baardwijk A, Bosmans G, Dekker A, van Kroonenburgh M, Boersma L, Wanders S, et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced nonsmall cell lung cancer (NSCLC) patients. Radiother Oncol 2007;82:145-52.
68. Haas RL, de Jong D, Valdes Olmos RA, Hoefnagel CA, van den Heuvel I, Zerp SF, et al. In vivo imaging of radiationinduced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys 2004;59:782-7. (Pubitemid 38748743)
69. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl JMed 2006;354:496-507. (Pubitemid 43200300)
70. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005;46:983-95. (Pubitemid 43733514)
71. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82. (Pubitemid 29512308)
72. Murano T, Tateishi U, Iinuma T, Shimada N, Daisaki H, Terauchi T, et al. Evaluation of the risk of radiation exposure from new 18FDG PET/CT plans versus conventional X-ray plans in patients with pediatric cancers. Ann Nucl Med 2010;24:261-7.
73. Yao M, Smith RB, Hoffman HT, Funk GF, Lu M, Menda Y, et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer - a long-term outcome report. Int J Radiat Oncol Biol Phys 2009;74:9-14.
74. Yao M, Smith RB, Graham MM, Hoffman HT, Tan H, Funk GF, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005;63:991-9. (Pubitemid 41505274)
75. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008;112:3989-94.
76. Muller H, Enghardt W. In-beam PET at high-energy photon beams: a feasibility study. Phys Med Biol 2006;51:1779-89.
77. Parodi K, Enghardt W, Haberer T. In-beam PET measurements of beta+ radioactivity induced by proton beams. Phys Med Biol 2002;47:21-36. (Pubitemid 34071346)
78. Fiedler F, Priegnitz M, Julich R, Pawelke J, Crespo P, Parodi K, et al. In-beam PET measurements of biological half-lives of 12C irradiation induced beta+-activity. Acta Oncol 2008;47:1077-86.
79. 7Li3+ irradiation induced beta+-activity. Phys Med Biol 2008;53:4443-53.
80. Sommerer F, Cerutti F, Parodi K, Ferrari A, Enghardt W, Aiginger H. In-beam PET monitoring of mono-energetic (16)O and (12)C beams: experiments and FLUKA simulations for homogeneous targets. Phys Med Biol 2009;54:3979-96.
81. Andreo P. On the clinical spatial resolution achievable with protons and heavier charged particle radiotherapy beams. Phys Med Biol 2009;54:N205-15.
82. Enghardt W, Fiedler F, Möckel D, Parodi K. In-beam PET for radiotherapy monitoring. Available from: http://www.hzdr.de/db/Cms?pOid= 24771&pNid=84.
83. Nishio T, Miyatake A, Ogino T, Nakagawa K, Saijo N, Esumi H. The development and clinical use of a beam ON-LINE PET system mounted on a rotating gantry port in proton therapy. Int J Radiat Oncol Biol Phys 2010;76:277-86.